Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919122 · ClinicalTrials.gov registry record
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
A clinical trial of Metastatic Renal Cell Carcinoma, sponsored by Duke University.
- Active
- Registry status
- 468
- Enrollment target
- 14
- Study locations
NCT04919122 is a study of Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by Duke University. The registered enrollment target is 468 participants, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (257% higher). The trial reports 14 study locations across 12 states.
The verdict
NCT04919122, a study of Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- 468 participants
- Enrollment target
- 14
- Study locations
Study Summary
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
Conditions Studied
Study Locations (14)
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
- Duke University - Durham
Pennsylvania
- Geisinger Clinic - Danville
- University of Pittsburgh - Pittsburgh
Iowa
- State University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Ochsner Clinic Foundation d/b/a Ochsner Health - New Orleans
Maryland
- The Johns Hopkins University - Baltimore
Michigan
- The Regents of the University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919122
The ClinicalTrials.gov registry entry for NCT04919122 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (257% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04919122 reports 14 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, Pennsylvania, Iowa.
Frequently Asked Questions
What is clinical trial NCT04919122 about?
NCT04919122 is a clinical study titled "Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma". ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
What is the current status of trial NCT04919122?
This trial is currently active not recruiting. The enrollment target is 468 participants. The study started on 2022-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04919122 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.
Who is sponsoring clinical trial NCT04919122?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919122 being conducted?
This trial has 14 study locations across Iowa, Kansas, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.